Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-10-04
2005-10-04
Kemmerer, Elizabeth C. (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000, C530S350000, C530S388220, C514S012200, C436S501000, C424S130100, C424S198100, C435S002000, C435S069500, C536S023500
Reexamination Certificate
active
06951839
ABSTRACT:
The present application is directed to the discovery that hedgehog gene products, and signal transduction pathways involving hedgehog, are involved in maturation of T lymphocytes. Certain aspects of the invention are directed to preparations of hedgehog polypeptides, agonists, antagonists, or other molecules which regulate patched or smoothened signalling, and their uses as immunomodulatory agents.
REFERENCES:
patent: 4868116 (1989-09-01), Morgan et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5096815 (1992-03-01), Ladner et al.
patent: 5176996 (1993-01-01), Hogan et al.
patent: 5198346 (1993-03-01), Ladner et al.
patent: 5223408 (1993-06-01), Goeddel et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5256775 (1993-10-01), Froehler
patent: 5264564 (1993-11-01), Matteucci
patent: 5266488 (1993-11-01), Ordahl et al.
patent: 5286654 (1994-02-01), Cox et al.
patent: 5328470 (1994-07-01), Nabel et al.
patent: WO 88/06630 (1988-09-01), None
patent: WO 89/02468 (1989-03-01), None
patent: WO 89/05345 (1989-06-01), None
patent: WO 89/07136 (1989-08-01), None
patent: WO 90/02809 (1990-03-01), None
patent: WO 92/07573 (1992-05-01), None
patent: WO 92/09690 (1992-06-01), None
patent: WO 92/15679 (1992-09-01), None
patent: WO 93/09222 (1993-05-01), None
patent: WO 98/30520 (1993-08-01), None
patent: WO 93/25234 (1993-12-01), None
patent: WO 95/18856 (1995-07-01), None
patent: WO 95/31560 (1995-11-01), None
patent: WO 96/17924 (1996-06-01), None
patent: WO 96/29411 (1996-09-01), None
patent: WO 00/74706 (2000-12-01), None
patent: WO 02/080952 (2002-10-01), None
Bowie et al., 1990, Science 247:1306-1310.
Alexander et al., Proc. Natl. Acad. Sci. 89(3352-3356) 1992.
Lahana R., Drug Discovery Today, 4(10)447-448, 1999.
Horrobin, DF, British Med. Journal, 322(7280)239, Jul. 2003.
Stull and Iacovitti, Experimental Neurobiology 169(1)36-43, 2001.
Lowery er al., J. Immunology 169(4)1869-75, 1999.
Bubec et al., ALCOHOL 13(6)55-537, 1996.
Bryce et al., Immunopharmacology 41(139-146)1999.
Shah, D. et al. Reduced Thymocyte Development in Sonic Hedgehog Knockout Embryos, The Journal of Immunology. pp. 2296-2306 (2004).
Lin, J. et al. Increased cAMP and cAMP-Dependent Protein Kinase Activity Mediate Anti-CD2 Induced Suppression of Anti-CD3-Driven Interleukin-2 Production and CD25 Expression. Pathobiol. 63, 175-187 (1995).
Arkin and Yourvan, 1992, “An algorithm for protein engineering: simulations of recursive ensemble mutagenesis”, Proc. Natl. Acad. Sci. USA 89:7811-7815.
Armentano et al., 1990, “Expression of human factor IX in rabbit hepatocytes by retrovirus-mediated gene transfer: potential for gene therapy of hemophillia B”, Proc. Natl. Acad. Sci. USA 87:6141-6145.
Baldwin et al., 1984, “Cloning of the luciferase structural genes fromVibrio harveyiand expression of bioluminescence inEscherichia coli”, Biochemistry 23:3663-3667.
Barbas et al., 1992, “Semisynthetic combinatorial antibody libraries: a chemical solution to the diversity problem”, Proc. Natl. Acad. .Sci. USA 89:4457-4461.
Bass et al., 1990, “Hormone phage: an enrichment method for variant proteins with altered binding properties”, Proteins 8:309-314.
Bear et al., 1992, “Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR)”, Cell 68:809-818.
Ben-Bassat et al., 1987, “Processing of the initiation methionine from proteins: properties of theEscherichia colimethionine aminopeptidase and its gene structure”, J. Bacteriol. 169:751-757.
Benoist et al., 1981, “In vivo sequence requirements of the SV40 early promotor region”, Nature 290:304-310.
Berkner et al., 1988, “Development of adenovirus vectors for the expression of heterologous genes”, Biotechniques 6:616-629.
Borle, 1990, “An overview of techniques for the measurement of calcium distribution, calcium fluxes, and cytosolic free calcium in mammalian cells”, Environ. Health Perspect. 84:45-56.
Bumcrot et al., 1995, “Proteolytic processing yields two secreted forms of sonic hedgehog”, Mol. Cell. Biol. 15:2294-2303.
Chang et al., 1994, “Products, genetic linkage and limb patterning activity of a murine hedgehog gene”, Development 120:3339-3353.
Chen et al., “Gene therapy for brain tumors: regresssion of experimental gliomas by adenovirus-mediated gene transfer in vivo”, Proc. Natl. Acad. Sci. USA 91:3054-3057.
Chowdhury et al. 1991, “Long-term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits”, Science 254:1802-1805.
Clackson et al., 1991, “Making antibody fragments using phage display libraries”, Nature 352:624-628.
Cullen and Malim, 1992, “Secreted placental alkaline phosphatase as a eukaryotic reporter gene”, Methods Enzymol. 216:362-368.
Cwirla et al., 1990, “Peptides on phage: a vast library of peptides for identifying ligands”, Proc. Natl. Acad. Sci. USA 87:6378-6382.
Dai et al., 1992, “Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo”, Proc. Natl. Acad. Sci. USA 89:10892-10895.
Dann et al., 1986, “Human renin: a new class of inhibitors”, Biochem. Biophys. Res. Commun. 134:71-77.
Danos and Mulligan, 1988, “Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges”, Proc. Natl. Acad. Sci. USA 85:6460-6464.
Delgrave et al., 1993, “Recursive ensemble mutagenesis”, Protein Eng. 6:327-331.
Dev et al., 1994, Electrochemotherapy—a novel method of cancer treatment, Cancer Treat. Rev. 20:105-115.
Devlin et al., 1990, “Random peptide libraries: a source of specific protein binding molecules”, Science 249:404-406.
DeWet et al., 1987, “Firefly luciferase gene: structure and expression in mammalian cells”, Mol. Cell Biol. 7:725-737.
Eglitis et al., 1985, “Gene expression in mice after high efficiency retroviral-mediated gene transfer”, Science 230:1395-1398.
Ekker et al., 1995, “Patterning activities of vertebrate hedgehog proteins in the developing eye and brain”, Curr. Biol. 5:944-955.
Ellison et al., 1991, “Epitope-tagged ubiquitin. A new probe for analyzing ubiquitin function”, J. Biol. Chem. 266:21150-21157.
Ellman et al., 1958, “A colormetric method for determining low concentrations of mercaptans”, Arch. Biochem. Biophys. 74:443.
Engebrecht and Silverman, 1984, “Identification of genes and gene products necessary for bacterial bioluminescence”, Proc. Natl. Acad. Sci. USA 81:4154-4158.
Ettienne-Julan et al., 1992, “The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker”, J. Gen. Virol. 73 (Pt 12):3251-3255.
Ewenson et al., 1986, “Ketomethylene pseudopeptide analogues of substance P: synthesis and biological activity”, J. Med. Chem. 29:295-299.
Ferry et al., 1991, “Retroviral-mediated gene transfer into hepatocytes in vivo”, Proc. Natl. Acad. Sci. USA 88:8377-8381.
Fuchs et al., 1991, “Targeting recombinant antibodies to the surface ofEscherichia coli: fusion to a petidoglycan associated lipoprotein”, Bio/Technology 9:1370-1371.
Gallop et al., 1994, “Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries”, J. Med. Chem. 37:1233-1251.
Gordon et al., 1985, “Design of peptide derived amino alcohols as transition-state analog inhibitors of angiotensin converting enzyme”, Biochem. Biophys. Res. Commun. 126:419-426.
Goud et al., 1983, “Antibody-mediated binding of a murine ecotropic Moloney retroviral vector to human cells allows internalization but not the establishment of the proviral state”, Virology 163:251-254.
Goward et al, 1992, “
Brannock Michael
Curis, Inc.
Kemmerer Elizabeth C.
Ropes & Gray LLP
LandOfFree
Methods and compositions for regulating lymphocyte activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for regulating lymphocyte activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for regulating lymphocyte activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3483651